Additionally, RIG-I has been identified not only as an anti-oncogene but also as a biomarker for the efficacy of IFN-α treatment for HCC, emphasizing its critical role in modulating the growth and treatment responses of tumors (6, 87). The gene discussed is RIGI; the disease is hepatocellular carcinoma.